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analysis was performed on real-world observational data from the years 2010-2013 
in The Netherlands. Data on use and adherence was collected, in patients who were 
dispensed bupropion or varenicline in community pharmacies for the first time. 
Adherence was defined a using minimal 80% of the in guidelines recommended 
duration and intensity of use. Results: The study cohort consisted of 4,412 users of 
pSCT. The number of prescriptions was stable at 0.5 prescriptions per 1,000 inhabit-
ants (dispensing prevalence, dp) during 2010. The prevalence was on average 0.8 
dp, with peaks in the the 1st and 4th quarters of 2011. In 2012, the prevalence was 
stable at 0.4 dp. In 2013 was on average 0.5 dp, with a small peak in the 1st quarter. 
Adherence was 18% in 2010 and 2012 (non-reimbursement period), and 21% in 2011 
and 2013 (reimbursement period). ConClusions: Not only the likelihood of start-
ing smoking cessation, but also the extent of adherence to pharmacologic smoking 
cessation is higher during reimbursement. Increasing the awareness of health care 
providers on adherence issues is warranted.
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Monte-CaRlo SiMulation to eStiMate the health CaRe CoStS avoided 
With FlutiCaSone FuRoate/vilanteRol due to exaCeRbation Rate 
ReduCtion in SPaniSh CoPd PatientS
Mayoralas S.1, Huerta A.2, Parrondo J.2, Rubio-Terrés C.3, Rubio-Rodríguez D.3
1Hospital Ramón y Cajal, Madrid, Spain, 2GlaxoSmithKline, Madrid, Spain, 3Health Value, Madrid, 
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objeCtives: Exacerbations are considered one of the main drivers of costs of 
Chronic Obstructive Pulmonary Disease (COPD). In moderate to severe COPD 
patients with a history of exacerbations, the addition of an inhaled corticosteroid 
(ICS) to a long acting β 2 agonist (LABA) has been associated with a decreased rate of 
exacerbations versus treatment with LABA alone. This study aims to estimate the 
health care costs that the addition of the ICS Fluticasone Furoate (FF) to the LABA 
vilanterol (VI) could avoid versus LABA monotherapy in Spanish patients due to 
the reduction of the rate of exacerbations. Methods: The number of moderate 
to severe COPD patients > 40 years old with a history of exacerbation potentially 
treated with FF+VI was estimated from Spanish prevalence data. 1-year Monte-Carlo 
simulations (one simulation per patient) were developed to simulate the number of 
moderate and severe exacerbations and the health care costs avoided with FF+VI 
versus VI from the National Health System (NHS) perspective. Monte-Carlo simula-
tion was chosen as it allows simulating the effect of changes in different param-
eters obtained from clinical studies to describe real-life distributions. Parameters 
used in the simulations were the yearly rate of moderate-severe exacerbations 
with FF+VI and VI obtained from pooled-analysis of two head-to-head clinical trials 
(NCT01009463 and NCT01017952) and the costs of moderate and severe exacerba-
tions obtained from an observational study in real-life Spanish setting. Results: 
18,098 patients were included. FF+VI could avoid 7,424 moderate and severe exac-
erbations (95% confidence interval 7,411; 7,438) vs VI. The reduction in the number 
of exacerbations could lead to average health care costs avoided to the NHS of 3,278, 
382€ (3,066, 703€ ; 3,336, 392€ ) in a year. ConClusions: Treatment with FF+VI could 
decrease the economic burden associated with COPD reducing the health care costs 
for the Spanish NHS due to the decreased rate of exacerbations compared with 
LABA (VI) monotherapy.
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deteRMination oF availability oF antiMiCRobial PRePaRationS FoR 
tReatMent oF CoMMunity-aCquiRed PneuMonia in ukRaine
Iakovlieva L., Vasilieva A., Rybka A., Yurchenko O.
National University of Pharmacy, Kharkiv, Ukraine
objeCtives: Data of british specialists show, that 5-11 out of 1000 adults have com-
munity-acquired pneumonia (CAP) every year, which is 5-12% of all cases of lower 
respiratory tract infections. The rate of CAP took over 3% in the structure of total 
respiratory organs disease rate in Ukraine within years 2007-2011. Methods: The 
data of use of antimicrobial preparations (AP): cephalosporins (ceftriaxone), penicil-
lins (amoxicillin and enzyme inhibitor), macrolides (azithromycin) and fluoroqui-
nolones (ciprofloxacin, levofloxacin) for CAP treatment in Kharkiv hospital were 
used. Analysis of affordability as of index of payment capacity (Ca. s.) of trade names 
(TNs) provided in pharmaceutical market of Ukraine on indicated INN has been 
carried out to determine the availability of such preparations for wider population 
of Ukraine. Results: Results of the AP affordability analysis made in five groups of 
INN, showed, that the ratio of therapy of high, middle and low availability for each 
AP group is different, but in all pharmacological groups except for ceftriaxone group, 
highly available therapy prevails. Percentage of highly available preparations in the 
studied groups of INN is: azitromycin (92.2%) > ciprofloxacin (74.3%) > amoxicillin 
and enzyme inhibitor (67.5%) > ceftriaxone (49.02%) > levofloxacin (46.94 %). As of 
preparations of middle availability, costing 5% - 15% of average monthly salary, cef-
triaxone preparations are most (49.02%), azitromycin preparations are least (6.49%). 
There are no low availability preparations in ciprofloxacin fluoroquinolone group. 
Cephalosporins and macrolides group preparations have one AP of low availability. 
Pharmacotherapy with application of preparations-analogous to levofloxacin, is 
costly, as 32.7% of preparations of this group are preparations of low availability 
(16 AP). ConClusions: Antibacterial preparations needed for treatment of CAP 
are present in the pharmaceutical market of Ukraine in wide range of preparations 
and cost. It makes them available to various social groups.
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hoW MuCh the aPPRoPRiate tobaCCo PRiCe Would be?: a diSCRete 
ChoiCe exPeRiMent oF GeneRal PubliC in JaPan
Igarashi A.1, Goto R.2
1University of Tokyo, Graduate School of Pharmaceutical Sciences, Tokyo, Japan,, 2Kyoto University, 
Kyoto, Japan
objeCtives: Though tobacco price increases are effective in reducing tobacco con-
sumption and prevalence of smoking, tobacco-tax in Japan is still lower than those in 
other developed countries. General public, particularly non-smokers, may think that 
inflammatory formulations were discontinued during 12 months after asthma diag-
nosis. ConClusions: Asthma treatment utilization patterns reflect poor asthma 
control among newly diagnosed elderly patients, and initiation of anti-inflammatory 
treatment after asthma diagnosis appears to be inconsistent with asthma manage-
ment guidelines.
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doCtoRS’ FailuRe in obSeRvanCe oF the CoPd ManaGeMent GuidelineS: 
CaSe oF the CZeCh RePubliC
Tichopad A.1, Koblizek V.2, Kolek V.3, Pecen L.1
1CEEOR s.r.o., Prague, Czech Republic, 2Charles University Faculty of Medicine and University 
Hospital, Hradec Králové, Czech Republic, 3Olomouc University Hospital, Olomouc, Czech Republic
objeCtives: The primary objective of this study was to examine the accuracy of 
the GOLD 2011 strategy implementation among the Czech respiratory specialists, 
esp. with respect to the patients’ classification. The secondary objective was to 
explore what effect a misclassification has on inadequate use of inhaled corticos-
teroids (ICS). Methods: Multicentre cross-sectional study was conducted among 
COPD specialists, consisting of general questionnaire and patient-specific forms. A 
subjective classification into the GOLD 2011 groups as practiced by the health care 
professionals was examined and then compared with the objective classification 
achieved by rigorous software-computed classification. Adequacy of the ICS pre-
scription was evaluated with regard to the subjective classification. Results: GOLD 
2011 were claimed to be the leading guidelines for 143 out of 144 specialists involved, 
often accompanied by CPPS guidelines (83.3%) and the ACP/ACCP/ATS/ERS standards 
(50.7%). Based on 1355 patient forms, a discrepancy between the subjective and 
objective classification was found in 32.8% of cases. The most common reason for 
incorrect classification was erroneous symptoms assessment resulting in either 
under-estimation in 23.9% of cases and over-estimation in 8.9% of the examined 
patients’ records. Specialists seeing more than 120 patients per month were most 
likely to misclassify their condition, i. e. in 36.7% of all seen patients. In general, 
whilst examining the subjectively-driven ICS prescription, it was found that 19.5% 
of patients received ICS incorrectly, while in 12.2% of cases the ICS was erroneously 
omitted. Furthermore, with consideration to the objectively computed classifica-
tion, it was discovered that 15.4% received ICS unnecessarily, whereas in 15.8% of 
cases the ICS was not prescribed though, in fact, it would be adequate seeing the 
patient’s condition. Women failed in correct prescription more frequently than men, 
predominantly by overprescribing ICS. ConClusions: Despite high awareness of 
the GOLD 2011 guidelines, its implementation is insufficient. Czech specialists tend 
to either under-classify or overuse the ICS.
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SoCial Media MeetS PoPulation health: a SentiMent and 
deMoGRaPhiC analySiS oF tobaCCo and e-CiGaRette uSe aCRoSS the 
“tWitteRSPheRe”
Clark E.M.1, Jones C.2, Gaalema D.1, White T.J.1, Redner R.1, Everett R.1, Dodds P.S.1, Couch M.2, 
Danforth C.1
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objeCtives: Twitter, a popular social media outlet, has become a useful tool for 
the study of social behavior through user interactions called tweets. The location 
time, and message content of tweets provide invaluable social and demographic 
information for an applied comparison of social behaviors across the world. Our 
goal is to determine the density and sentiment surrounding tobacco and e-cigarette 
tweets and link prevalence of word choices to tobacco and e-cigarette use at various 
localities. Methods: All tweets with geo-spatial coordinates are salvaged from the 
twitter-feed, representing approximately 1% of the entire twitter-sphere. Pattern 
matching by tobacco and e-cigarette related keywords yield approximately 20,000 
affiliated tweets per month from North America. The emotionally charged words 
that contribute to the positivity of various subsets of regional tweets are quantita-
tively measured using hedonometrics. We examined the density of these behavioral 
tweet indicators by region and tested the relationship between tweeted smoking 
sentiments and time-space-type coordinates over a 4-month span. Results: For 
states with ≥ 600 tobacco related tweets (N= 30), we find a strong positive correla-
tion (Pearson’s r= 0.54, p< 0.01) between the relative tweet density per state and 
the average positivity of tobacco related tweets. However, state-to-state sentiment 
comparisons suggest the attitude toward tobacco use can vary. We also explore 
the relationship between the ratio of tobacco tweets per state-to-state smoking 
rate estimates. Our results illustrate significant variation in smoking sentiments 
by state and at varying regional scopes. ConClusions: It is anticipated that real-
time analysis of nicotine and tobacco products using tweets will allow for more 
targeted forms of health policy planning and intervention. Regional density of 
nicotine and tobacco use related tweets yield insight to the prevalence of tobacco 
usage per capita. Sentiment analysis across the twitter-sphere can help illuminate 
hazardous health behavioral trends, which may lead to better targeting of health 
behavior interventions.
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SuStainable PoliCy: hiGheR MediCation uSe & adheRenCe duRinG 
ReiMbuRSeMent oF PhaRMaColoGiC SMokinG CeSSation tReatMentS
Van Boven J.F., Vemer P.
University of Groningen, Groningen, The Netherlands
bACkgRound: The discussion on the reimbursement of Smoking Cessation 
Treatment (SCT) has known many stages in The Netherlands. From January 2011, 
SCTs were reimbursed, until January 2012 when the reimbursement of nicotine 
replacement therapies (NRTs) and pharmacotherapeutic SCT (pSCT) was discon-
tinued. As of 2013, NRTs and pSCTs were again reimbursed for a maximum of one 
attempt per calendar year, provided they are accompanied by behavioural coun-
selling. objeCtives: To assess the impact of changes in reimbursement policy 
of pSCT on use and adherence. Methods: A retrospective dispensing database 
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CoSt-eFFeCtiveneSS oF oMaliZuMab in ChRoniC idioPathiC uRtiCaRia 
ReFRaCtoRy to h1-antihiStaMineS in tuRkey
Tatar M.1, Sezen S.2, Senturk A.3, Balp M.M.4, Saylan M.2, Keskinaslan A.2
1Hacettepe University, Ankara, Turkey, 2Novartis Pharma, Istanbul, Turkey, 3Polar Polar Health 
Economics & Policy, Ankara, Turkey, 4Novartis Pharma AG, Basel, Switzerland
objeCtives: Omalizumab is a humanised anti-IgE recombinant monoclonal anti-
body approved in Turkey for treatment of chronic idiopathic (or spontaneous) urti-
caria (CIU) in patients resistant to standard treatment. We aimed to assess the 
cost-effectiveness of omalizumab compared with the standard care in the treatment 
of CIU patients in Turkey. Methods: A Markov model of 10 years horizon was devel-
oped to estimate costs and outcomes associated with omalizumab 300mg/every 4 
weeks and standard of care for 24 weeks (SoC= licensed dose H1 antihistamines) 
using data from two phase III studies (ASTERIA I&II includes patients with CIU 
refractory to licensed dose of H1-antihistamines). The study was undertaken from 
a Turkish health care payer perspective. At the end of this period, omalizumab was 
stopped and background medication continued. Patients who have responded were 
retreated by the same strategy upon relapse (UAS7 ≥ 16 or ≥ 28). We used Urticaria 
Activity Score 7 (UAS7) to measure the outcome of the treatment and we used 
symptom free days (UAS7 ≤ 6) as the outcome measure in this cost effectiveness 
analysis. Resource utilization data were obtained via a Delphi panel. Unit costs 
were taken from the Social Security Institution’s official list. Costs and outcomes 
were evaluated over a lifetime and discounted at 3%. Results were presented as 
incremental cost/symptom free days. Results: The incremental symptom free 
days with omalizumab versus SoC was 27,965 days and the incremental cost was 
1,610,349 Turkish Liras for 100 patients over 10 years. The incremental cost per 
symptom free day was 57.59 Turkish Liras. One-way sensitivity analyses confirmed 
the robustness of the model results. ConClusions: CIU affects the quality of life 
of patients and is associated with direct and indirect costs to payers and society. 
We believe that omalizumab 300mg Q4wks is a cost-effective treatment option for 
patients with refractory CIU in Turkish setting.
PSS4
outCoMeS oF PatientS With neovaSCulaR aGe-Related MaCulaR 
deGeneRation (naMd) in GReeCe undeR RanibiZuMab
Yfantopoulos J.1, Rouvas A.2, Chatzaras A.1, Xanthopoulou P.2, Theodosiadis P.2
1National and Kapodistrian University of Athens, Athens, Greece, 2Attikon University Hospital of 
Athens, Chaidari, Greece
objeCtives: To evaluate the efficacy of treatment with ranibizumab in a sample of 
Greek patients with nAMD. Methods: In this observational, non-interventional, 
retrospective study, 194 cases with nAMD were enrolled from the Ophthalmology 
Department of “Attikon” hospital. Patients treated with ranibizumab for at least one 
year in one eye under routine clinical practice, and had at least one follow-up visit, 
were considered eligible. Patients participating in another study and/or were receiv-
ing pharmaceutical product containing VEGF inhibitors were excluded. Primary end-
points were the mean change in Best Corrected Visual Acuity (BCVA), and in Central 
retinal thickness (CRT), assessed by Optical Coherence Tomography. Results: 
The average BCVA score per eye at baseline was 0.284 in decimal points (Snellen 
equivalent≈ 20/84; ETDRS letters≈ 57.7), which improved at final visit (≈14 months 
after baseline) reaching 0.336 (Snellen equivalent≈ 20/60; ETDRS letters≈ 61.3), i.e. 
6,33% or approximately 3.7 ETDRS letters improvement (p< 0.001, r= 0.317) with 4.9 
ranibizumab injections overall (4.3 injections/year). CRT similarly improved, as it 
decreased by 28.4%, from 290.31 to 207.77 μ m (p< 0.001, r= 0.683). An extra ranibi-
zumab injection per eye per year, increased the odds of an at least 0.1 increase in 
BCVA from baseline to last visit by 20.8% (95%CI 1.068-1.366), and an at least 0.2 
increase by 15.7% (95%CI 1.013-1.322). ConClusions: Ranibizumab provides sig-
nificant benefit in patients with nAMD under routine clinical practice by improving 
BCVA and reducing CRT, benefit which may be more important in a more frequent 
dosing regimen.
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ReSultS oF a deCubituS PRevention and Wound CaRe PRoJeCt
Dozsa C.1, Borcsek B.2
1University of Miskolc, Miskolc, Hungary, 2Med-Econ Ltd., Veroce, Hungary
objeCtives: Background: The project focused on the preventive use, effectiveness 
and the better knowledge about the potential effects and mechanisms of dress-
ings. Aims: To improve the effectiveness of wound care, to prevent effectively the 
appearance of pressure ulcers during hospitalization. Methods: During 2 months 
of the project 80 patients of 3 active and 2 chronic care departments were involved, 
treatment of 84 pressure ulcers of 46 patients occurred. After the health check the 
attachment of dressings and the wound management were carried out according 
to the protocols and were documented on special datasheets. Subsequently, the 
checking and processing of questionnaires – continuing the monitoring of patient 
pathways – were done. Results: Pressure ulcers did not develop in case of 79% of 
the patients after prevention, effectiveness of targeted prevention reached 95.5%. 
The incidence of decubitus fell by 1.6-1.7 % in the project (formation rate was 58.8-
90.9 % lower in average). In the background of successful prevention min. 3-day use 
was observed, but even use of 1-1 preventive dressing was effective. The average 
length of wound care was14 days, frequency was 8.2 times/patient. The healed or 
recovering wounds were more frequently treated, but rather for more days, how-
ever, their treatment cost less than the average and those wounds which were not 
healing. ConClusions: Wound care starts with prevention. The quality of wound 
care should not decrease after the patient’s discharge, the home follow-up would 
be essential, nevertheless its “best practices” has not spread widely in Hungary yet. 
In the short term Decubitus Team doctors should be involved in patients’ discharge 
planning, however in the long term creation of a so-called Wound Care Centre could 
offer a sustainable solution. Hereinafter controlled trials of higher number of cases 
could prove the cost-effectiveness of intelligent dressings in wider aspects of the 
health care system.
tobacco tax is important as a source of revenue. The objectives of this research is to 
quantitatively assess about how general public value several aims of tobacco policy 
and the amount of tax revenue and to estimate “ideal” tobacco price where the price 
elasticity of tobacco consumption is given. Methods: We conducted a web-based 
survey from 9-15, Aug 2012 including a discrete choice experiment (DCE) to elicit 
general public’s preference for targeted smoking rate, tax revenue, tobacco policy for 
the younger generation and the usage of tax. Then, we numerically forecast general 
publics’ support rate of a tobacco policy as a function of tobacco price where price 
elasticity is given. Results: 1,077 completed questionnaires and were eligible for 
analysis. They statistically prefer the tobacco policy which results in lower prevalence 
of smokers, higher tax revenue, targeted for young people and tax revenue is used for 
general purposes. Given the price elasticity of 0.3, 0.4 and 0.5, highest tobacco price, 
which acquire the highest support from general public, was around JPY871 (EUR6.2), 
JPY555 (EUR4.0) and JPY454 (EUR3.2), respectively. ConClusions: The present price 
of cigarette per one pack is around JPY460 (EUR 3.3). When smokers are highly respon-
sive to price elevation and are successfully quit after the elevation, present price of 
cigarette is suitable when we consider public’s preference for tax revenue as well as 
normal policy measures. Rooms for further price elevations depends on the price 
elasticity of cigarette consumption.
SenSoRy SySteMS diSoRdeRS – Clinical outcomes Studies
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eFFiCaCy oF tReatMentS FoR MaCulaR oedeMa SeCondaRy to bRanCh 
Retinal vein oCCluSion: a netWoRk Meta-analySiS
Regnier S., Bezlyak V.
Novartis Pharma AG, Basel, Switzerland
objeCtives: To indirectly compare the efficacy of approved treatments for 
macular oedema secondary to branch retinal vein occlusion (BRVO). Methods: 
Randomized, controlled trials (RCTs) evaluating the efficacy at month 6 (or month 
12) of at least two of ranibizumab 0.5mg pro re nata (after 6 monthly doses), afliber-
cept 2.0mg monthly, dexamethasone implant (retreatment interval ≥ 6 months), 
laser photocoagulation or sham were identified from a published systematic 
review, congress abstracts, clinicaltrials. gov and Novartis data on file. Outcomes of 
interest were the mean change in best-corrected visual acuity (BCVA, measured as 
Early Treatment Diabetic Retinopathy Study letters), and the percentage of patients 
gaining ≥ 15 letters. For two studies, the standard deviation around mean BCVA 
gain was estimated. A Bayesian network meta-analysis with random treatment 
effects was used to compare mean BCVA gains and odds ratios (ORs) for gaining 
≥ 15 letters. Results: The analysis included seven RCTs. Patient-level data for 
three ranibizumab trials were re-analysed to match key inclusion criteria (BCVA 
and duration of disease at baseline) from aflibercept studies. Statistically signifi-
cant (p< 0.05) BCVA letter gains were found for ranibizumab monotherapy (+11.6), 
ranibizumab plus laser combination therapy (+10.1) and aflibercept (+10.1) versus 
laser, and for ranibizumab monotherapy versus dexamethasone (+8.0). ORs versus 
laser for gaining ≥ 15 letters were 3.24 (95% credible interval, 1.03–12.56; p< 0.05) 
and 3.07 (0.63–14.8) for ranibizumab monotherapy and aflibercept, respectively. 
Mean BCVA letter gains were numerically higher with ranibizumab monotherapy 
compared with aflibercept (+1.5 letters [-5.3–8.8]; OR for gaining ≥ 15 letters, 1.06 
[0.16–8.94]). The probability of being the most efficacious treatment based on let-
ters gained was 57% for ranibizumab, 15% for ranibizumab plus laser and 28% for 
aflibercept. ConClusions: The analysis confirms the superiority of ranibizumab 
over dexamethasone implant and laser therapy, and shows that ranibizumab has 
the highest likelihood of being the most efficacious treatment for BRVO.
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CoMPaRative eFFeCtiveneSS oF an aCellulaR SynthetiC MatRix aS an 
adJunCt to StandaRd CaRe in the tReatMent oF venouS and Mixed 
leG ulCeRS: ModelinG oF CliniCal data and Routine data
Augustin M.1, Gutknecht M.1, Anastasiadou Z.1, Heyer K.1, Harding K.2, Shannon R.J.3, 
Heinrichs E.L.4
1University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Cardiff University, Cardiff, 
UK, 3Global Health Economic Projects LLC, Clifton Park, NY, USA, 4Daresbury Innovation Centre, 
Daresbury, Cheshire, UK
objeCtives: Recently, advanced treatments such as topical growth factors, bio-
logical dressings, and tissue engineered products have been developed in order 
to promote healing as well as decrease the time to healing of chronic leg ulcers. 
Nevertheless, if standard care fails, there is no widely accepted, easy to use second-
line treatment primarily because most of these advanced treatments are expensive 
and need further evidence of effectiveness in everyday clinical practice. The purpose 
of our study was to assess the effectiveness of a new acellular synthetic matrix 
(ASM) as an adjunct to standard care, using healing time as endpoint, in venous and 
mixed leg ulcers in German everyday clinical practice. Methods: Prospective data 
on venous and mixed leg ulcers from a safety and effectiveness study on an acellular 
synthetic matrix was compared retrospectively to matched data from a German 
Registry of Chronic Wounds (DRCW) database containing German patients with 
equivalent leg ulcer disease, patient age and gender, baseline wound area, wound 
duration, same outcome measures, and comparable follow-up periods. The outcome 
of interest was healing time over 12-weeks of treatment. Results: Analysis using 
Kaplan Meier survival curves showed a mean of 73.1 days (95% CI: 66.4 - 79.9 days) 
to healing for acellular synthetic matrix treated ulcers, in comparison to 92.2 days 
(95% CI: 87.1 – 97.2 days) for equivalent ulcers treated in everyday clinical practice 
in Germany (Log rank test χ 2 11.46, p= 0.001). ConClusions: Results from this 
study predict a highly significant effect of a new acellular synthetic matrix as an 
adjunct to standard care in the repair of venous and mixed leg ulcers. The predic-
tive model may be useful in determining expected effectiveness of the acellular 
synthetic matrix in the treatment of venous and mixed leg ulcer patients treated 
in everyday clinical practice in Germany.
